Your browser is no longer supported. Please, upgrade your browser.
BIOC Biocept, Inc. monthly Stock Chart
Biocept, Inc.
Index- P/E- EPS (ttm)-3.96 Insider Own0.02% Shs Outstand13.40M Perf Week13.29%
Market Cap68.21M Forward P/E- EPS next Y-1.32 Insider Trans-33.48% Shs Float12.49M Perf Month12.28%
Income-25.40M PEG- EPS next Q-0.32 Inst Own14.90% Short Float2.95% Perf Quarter-5.42%
Sales10.70M P/S6.37 EPS this Y86.40% Inst Trans-11.98% Short Ratio0.62 Perf Half Y-7.45%
Book/sh1.89 P/B2.66 EPS next Y37.40% ROA-89.80% Target Price- Perf Year-1.99%
Cash/sh1.25 P/C4.04 EPS next 5Y40.00% ROE-125.10% 52W Range2.11 - 13.00 Perf YTD75.87%
Dividend- P/FCF- EPS past 5Y- ROI-178.70% 52W High-61.31% Beta0.89
Dividend %- Quick Ratio2.50 Sales past 5Y110.60% Gross Margin-32.30% 52W Low138.16% ATR0.36
Employees88 Current Ratio2.90 Sales Q/Q340.00% Oper. Margin- RSI (14)56.86 Volatility8.48% 7.80%
OptionableYes Debt/Eq0.11 EPS Q/Q82.60% Profit Margin- Rel Volume1.15 Prev Close5.12
ShortableYes LT Debt/Eq0.06 EarningsNov 12 AMC Payout- Avg Volume598.11K Price5.03
Recom2.00 SMA207.20% SMA508.75% SMA200-3.33% Volume689,150 Change-1.76%
Nov-14-17Reiterated Chardan Capital Markets Buy $2.50 → $1.50
Jun-02-17Initiated Chardan Capital Markets Buy $2.50
Jun-06-16Initiated ROTH Capital Buy $1.20
Aug-19-15Initiated H.C. Wainwright Buy $4
Jun-03-14Initiated Aegis Capital Buy $16
Dec-01-20 11:30AM  
Nov-20-20 08:00AM  
Nov-17-20 08:05AM  
Nov-16-20 06:47PM  
Nov-14-20 07:52AM  
Nov-12-20 04:05PM  
Nov-09-20 08:05AM  
Nov-05-20 08:05AM  
Nov-04-20 08:00AM  
Oct-29-20 08:05AM  
Oct-21-20 08:00AM  
Oct-06-20 08:00AM  
Oct-05-20 08:00AM  
Oct-01-20 08:00AM  
Sep-24-20 08:48AM  
Sep-23-20 08:00AM  
Sep-21-20 06:21PM  
Sep-16-20 08:00AM  
Sep-14-20 08:00AM  
Sep-09-20 08:00AM  
Sep-08-20 08:00AM  
Sep-04-20 04:28PM  
Aug-31-20 06:12PM  
Aug-27-20 08:00AM  
Aug-24-20 08:00AM  
Aug-20-20 08:30AM  
Aug-19-20 08:00AM  
Aug-18-20 08:00AM  
Aug-17-20 07:38PM  
Aug-13-20 08:00AM  
Aug-12-20 04:05PM  
Aug-06-20 11:44AM  
Aug-05-20 06:00PM  
Aug-03-20 08:00AM  
Jul-31-20 02:43PM  
Jul-16-20 08:05AM  
Jun-30-20 08:05AM  
Jun-26-20 10:04PM  
Jun-24-20 08:05AM  
Jun-22-20 08:05AM  
Jun-05-20 08:05AM  
May-29-20 08:30AM  
May-20-20 08:05AM  
May-14-20 08:05AM  
May-13-20 04:05PM  
Apr-29-20 08:05AM  
Apr-28-20 08:05AM  
Apr-20-20 08:05AM  
Apr-14-20 09:00AM  
Apr-13-20 09:54AM  
Apr-09-20 07:17PM  
Apr-02-20 08:05AM  
Apr-01-20 07:53PM  
Mar-28-20 08:23AM  
Mar-26-20 08:05AM  
Mar-25-20 04:05PM  
Mar-18-20 08:30AM  
Mar-11-20 09:23AM  
Mar-09-20 08:05AM  
Mar-05-20 08:30AM  
Mar-02-20 10:48AM  
Feb-14-20 08:05AM  
Feb-10-20 08:05AM  
Feb-04-20 08:05AM  
Jan-14-20 08:05AM  
Jan-12-20 08:22AM  
Jan-08-20 09:00AM  
Dec-12-19 08:00AM  
Dec-10-19 07:56AM  
Dec-09-19 09:15AM  
Dec-03-19 08:05AM  
Nov-21-19 08:05AM  
Nov-13-19 04:05PM  
Nov-07-19 08:05AM  
Nov-06-19 08:05AM  
Nov-04-19 08:05AM  
Oct-14-19 10:05AM  
Oct-07-19 08:05AM  
Oct-03-19 08:05AM  
Sep-03-19 08:05AM  
Aug-22-19 08:05AM  
Aug-13-19 08:05AM  
Aug-12-19 04:05PM  
Aug-05-19 08:05AM  
Aug-04-19 10:02PM  
Jul-22-19 08:05AM  
Jul-16-19 01:31PM  
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HALE DAVID FDirectorJun 12Sale0.56604335112Jun 12 09:42 PM
HALE DAVID FDirectorJun 12Sale0.56556309867Jun 12 09:42 PM